to deliver >20% earning CAGR over FY1517 led by (1) commercialisation of its Malaysia facility from Q4FY16, (2) resumption of Fidaxomicin supply contract with Merck, (3) commercial launch of Glargin (launched in Mexico and Columbia, approved in 18 other...